Allianz Asset Management GmbH lessened its stake in Ionis Pharmaceuticals, Inc. () by 99.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC.

Source: https://www.etfdailynews.com/2023/02/17/allianz-asset-management-gmbh-decreases-stock-position-in-ionis-pharmaceuticals-inc-nasdaqions/

BMO Capital Markets lowered their price target on Ionis Pharmaceuticals from $70.00 to $67.00 and set an “outperform” rating on the stock in a research report on Thursday, February 23rd.

Source: https://www.etfdailynews.com/2023/05/24/commonwealth-equity-services-llc-has-781000-holdings-in-ionis-pharmaceuticals-inc-nasdaqions/

Captrust Financial Advisors lifted its position in Ionis Pharmaceuticals by 21.1% in the second quarter.

Source: https://www.americanbankingnews.com/2023/08/18/ionis-pharmaceuticals-inc-nasdaqions-shares-acquired-by-connor-clark-lunn-investment-management-ltd.html

Citigroup raised shares of Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the company from $36.00 to $60.00 in a research note on Monday, July 31st.

Source: https://www.etfdailynews.com/2023/10/05/ionis-pharmaceuticals-nasdaqions-trading-up-3-1/

Creative Planning increased its holdings in shares of Ionis Pharmaceuticals by 9.1% in the 3rd quarter.

Source: https://www.etfdailynews.com/2023/01/30/4983-shares-in-ionis-pharmaceuticals-inc-nasdaqions-bought-by-ieq-capital-llc/

Finally, First Trust Advisors LP boosted its holdings in Ionis Pharmaceuticals by 30.1% during the third quarter.

Source: https://www.dailypolitical.com/2023/01/19/elizabeth-l-hougen-sells-8280-shares-of-ionis-pharmaceuticals-inc-nasdaqions-stock.html

Finally, Seven Eight Capital LP lifted its holdings in shares of Ionis Pharmaceuticals by 13.2% during the 4th quarter.

Source: https://www.etfdailynews.com/2023/08/21/california-state-teachers-retirement-system-has-5-90-million-holdings-in-ionis-pharmaceuticals-inc-nasdaqions/

In January, Ionis announced it had sold an interest in two of its medicines to Royalty Pharma for $500 million upfront and up to $625 million in additional payments based on future production.

Source: https://www.sandiegouniontribune.com/communities/north-county/carlsbad/story/2023-03-05/ionis-pharmaceuticals-plans-large-expansion-in-carlsbad

Ionis Pharmaceuticals, Inc. has a 12 month low of $29.68 and a 12 month high of $48.82.

Source: https://www.etfdailynews.com/2023/02/05/insider-selling-ionis-pharmaceuticals-inc-nasdaqions-evp-sells-177390-00-in-stock/

Piper Sandler lifted their price target on Ionis Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Thursday, January 19th.

Source: https://www.etfdailynews.com/2023/02/05/insider-selling-ionis-pharmaceuticals-inc-nasdaqions-evp-sells-177390-00-in-stock/

PNC Financial Services Group Inc. grew its holdings in Ionis Pharmaceuticals by 9.4% during the 1st quarter.

Source: https://www.etfdailynews.com/2023/08/03/amalgamated-bank-trims-position-in-ionis-pharmaceuticals-inc-nasdaqions/

Vanguard Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 5.0% during the third quarter.

Source: https://www.etfdailynews.com/2023/06/07/amalgamated-bank-grows-stock-holdings-in-ionis-pharmaceuticals-inc-nasdaqions/

Wipfli Financial Advisors LLC acquired a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $27,000.

Source: https://www.americanbankingnews.com/2023/04/21/analysts-issue-forecasts-for-ionis-pharmaceuticals-inc-s-q2-2023-earnings-nasdaqions.html